Kos Pharmaceuticals Appoints New Board Member

    Business Editors/Health/Medical Writers

    CRANBURY, N.J.--(BUSINESS WIRE)--Feb. 10, 2005--Kos Pharmaceuticals, Inc. (Nasdaq:KOSP) announced that William D. Pruitt has joined Kos' Board of Directors and will become the Chairman of its Audit Committee. Mr. Pruitt currently is also a member of the Audit Committee of PBSJ Corporation, a multi-disciplined engineering firm and is Chairman of the Audit Committee of Adjoined Consulting, Inc., a full-service management consulting firm with Global 2000 clients. He is also a Board Member of the University of Miami Alumni Association and on the Executive Committee of the Board of the Bankers Club.
    Mr. Pruitt was a managing partner for Florida, the Caribbean and Venezuela for Arthur Andersen LLP from 1980 until 1999, where his responsibilities included management of 1,000 personnel in seven cities and also included the operations of Andersen Consulting in South Florida from 1980-1989. He also served as a consultant to Ernst & Young for marketing in South Florida from 2002-2004. Mr. Pruitt has a Bachelor of Business Administration degree from University of Miami, and is a Certified Public Accountant.
    "Mr. Pruitt has had a great deal of experience in the accounting and business consulting industries and brings strong financial auditing and managerial skills to Kos," said Daniel Bell, Chairman of the Board of Directors. "We continue to be deeply committed to the highest standards of corporate governance and believe Mr. Pruitt's background and experience on audit committees of public companies, will be great assets to Kos. We are pleased to have him join our Board of Directors."
    Kos Pharmaceuticals, Inc. is a fully integrated specialty pharmaceutical company engaged in developing, commercializing, manufacturing and marketing proprietary prescription products for the treatment of chronic diseases. The Company's principal product development strategy is to reformulate existing pharmaceutical products with large market potential to improve safety, efficacy, or patient compliance. The Company currently markets Niaspan(R) and Advicor(R) for the treatment of cholesterol disorders, and Azmacort(R) for the treatment of asthma. Kos is developing additional products, has proprietary drug delivery technologies in solid-dose and aerosol metered-dose inhalation administration and is pursuing certain strategic business development and licensing opportunities.

--30--PP/mi*

CONTACT: Kos Pharmaceuticals, Inc., Cranbury Constance Bienfait, 954-331-3760

KEYWORD: FLORIDA NEW JERSEY INDUSTRY KEYWORD: PHARMACEUTICAL MEDICAL BIOTECHNOLOGY SOURCE: Kos Pharmaceuticals, Inc.

Copyright Business Wire 2005